Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICS-001 autologous PBMC angiogenic therapy in chronic limb-threatening ischemia
jRCT2052230115Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ICS-001 + autologous peripheral blood mononuclear cells in chronic limb-threatening ischemia (CLTI), arteriosclerosis obliterans and Buerger disease (TAO), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Incidence of treatment-related adverse events. Started Jun 2024; status: active, not recruiting.
02
Drugs
ICS-001 + autologous peripheral blood mononuclear cells
03
Conditions
chronic limb-threatening ischemia (CLTI)arteriosclerosis obliteransBuerger disease (TAO)
Beyond the preview
Go deeper on jRCT2052230115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2052230115.